Brief: Nexcella Announces Positive 58-Patient Nxc-201 Clinical Data 100% Overall Response Rate In Light Chain (Al) Amyloidosis
26/04/2023 22:56
April 26 (Reuters) - Immix Biopharma Inc IMMX.O :
* NEXCELLA ANNOUNCES POSITIVE 58-PATIENT NXC-201 CLINICAL
DATA:
100% OVERALL RESPONSE RATE IN LIGHT CHAIN (AL) AMYLOIDOSIS
Source text for Eikon: ID:nGNEyrmwx
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary